Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 In vitro proliferation assays with PI3K inhibitors in CT-26 and 4 T1 cell lines does not suggest in vivo efficacy by direct effect in tumor cells

From: PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

Incucyte proliferation data IC50 (μM)
Inhibitor Target 4 T1 CT26
Mean IC50 Mean IC50
AZD8835 PI3Kα/δ 13.913 4.591
AZD8186 PI3Kβ/δ > 30 14.597
GDC-0941 Pan-PI3K 5.004 0.486
PI-3065 PI3Kδ 5.61 9.27